Literature DB >> 25734345

Best practices for controlled ovarian stimulation in in vitro fertilization.

Emily S Jungheim1, Melissa F Meyer1, Darcy E Broughton2.   

Abstract

As applications for IVF have expanded over the years, so too have approaches to controlled ovarian stimulation (COS) for IVF. With this expansion and improved knowledge of basic reproductive biology, there is increasing interest in how COS practice influences IVF outcomes, and whether or not specific treatment scenarios call for personalized approaches to COS. For the majority of women undergoing COS and their treating physicians, the goal is to achieve a healthy live birth through IVF in a fresh cycle. Opinions on how COS strategy best leads to this common goal varies among centers as many clinicians base COS strategy not on evidence obtained through prospective randomized trials, but rather through observational studies and experience. Overall, when it comes to COS most clinicians recognize the approach should not be "one size fits all," but rather a patient-centered approach that takes the existing evidence into consideration. We outline the existing evidence for best practices in COS for IVF, highlighting how these practices may be incorporated into a patient-centered approach. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25734345      PMCID: PMC4627694          DOI: 10.1055/s-0035-1546424

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  50 in total

Review 1.  Natural cycle in vitro fertilisation (IVF) for subfertile couples.

Authors:  Thomas Allersma; Cindy Farquhar; Astrid E P Cantineau
Journal:  Cochrane Database Syst Rev       Date:  2013-08-30

2.  Decreased gonadotropin requirements in once daily compared to twice daily administration: a prospective, randomized study.

Authors:  Fady I Sharara; Michael G Collins; Galal Abdo
Journal:  J Assist Reprod Genet       Date:  2012-01-25       Impact factor: 3.412

Review 3.  Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles.

Authors:  Mohamed Afm Youssef; Hesham G Al-Inany; Mohamed Aboulghar; Ragaa Mansour; Ahmed M Abou-Setta
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

4.  What do consistently high-performing in vitro fertilization programs in the U.S. do?

Authors:  Bradley J Van Voorhis; Mika Thomas; Eric S Surrey; Amy Sparks
Journal:  Fertil Steril       Date:  2010-08-02       Impact factor: 7.329

5.  Acupuncture--help, harm, or placebo?

Authors:  David R Meldrum; Andrew R Fisher; Samantha F Butts; H Irene Su; Mary D Sammel
Journal:  Fertil Steril       Date:  2013-01-26       Impact factor: 7.329

Review 6.  Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.

Authors:  Leopoldo O Tso; Michael F Costello; Luiz Eduardo T Albuquerque; Régis B Andriolo; Cristiane R Macedo
Journal:  Cochrane Database Syst Rev       Date:  2014-11-18

Review 7.  Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.

Authors:  Mohamed A F M Youssef; Fulco Van der Veen; Hesham G Al-Inany; Monique H Mochtar; Georg Griesinger; Mohamed Nagi Mohesen; Ismail Aboulfoutouh; Madelon van Wely
Journal:  Cochrane Database Syst Rev       Date:  2014-10-31

8.  Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha.

Authors:  Jaroslaw Wechowski; Mark Connolly; Dirk Schneider; Philip McEwan; Richard Kennedy
Journal:  Fertil Steril       Date:  2008-03-12       Impact factor: 7.329

9.  What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders?

Authors:  Murat Berkkanoglu; Kemal Ozgur
Journal:  Fertil Steril       Date:  2009-04-14       Impact factor: 7.329

10.  Fertility patients' views about frozen embryo disposition: results of a multi-institutional U.S. survey.

Authors:  Anne Drapkin Lyerly; Karen Steinhauser; Corrine Voils; Emily Namey; Carolyn Alexander; Brandon Bankowski; Robert Cook-Deegan; William C Dodson; Elena Gates; Emily S Jungheim; Peter G McGovern; Evan R Myers; Barbara Osborn; William Schlaff; Jeremy Sugarman; James A Tulsky; David Walmer; Ruth R Faden; Edward Wallach
Journal:  Fertil Steril       Date:  2008-12-05       Impact factor: 7.329

View more
  10 in total

Review 1.  In Vivo and In Vitro Impact of Carbohydrate Variation on Human Follicle-Stimulating Hormone Function.

Authors:  George R Bousfield; Jeffrey V May; John S Davis; James A Dias; T Rajendra Kumar
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-09       Impact factor: 5.555

2.  Optimal Oocyte Number in Controlled Ovarian Stimulation with Gonadotropin-Releasing Hormone Agonist/Antagonist and Day 3 Fresh Embryo Transfer.

Authors:  Hoon Kim; Soo Jin Han; Yun Soo Hong; Sung Woo Kim; Seung-Yup Ku; Chang Suk Suh; Seok Hyun Kim
Journal:  Reprod Sci       Date:  2021-03-24       Impact factor: 3.060

3.  A call to action: unified clinical practice guidelines for oncofertility care.

Authors:  Jacqueline Sehring; Anisa Hussain; Lauren Grimm; Elisabeth Rosen; Jody Esguerra; Karine Matevossian; Erica Louden; Angeline Beltsos; Roohi Jeelani
Journal:  J Assist Reprod Genet       Date:  2021-03-11       Impact factor: 3.357

4.  Variability in the practice of fertility preservation for patients with cancer.

Authors:  Kasey A Reynolds; Natalia M Grindler; Julie S Rhee; Amber R Cooper; Valerie S Ratts; Kenneth R Carson; Emily S Jungheim
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

5.  Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys.

Authors:  C V Bishop; D M Lee; O D Slayden; X Li
Journal:  J Ovarian Res       Date:  2017-07-06       Impact factor: 4.234

6.  Effect of GnRH analogues for pituitary suppression on oocyte morphology in repeated ovarian stimulation cycles.

Authors:  Bianca Ferrarini Zanetti; Daniela Paes de Almeida Ferreira Braga; Amanda Souza Setti; Assumpto Iaconelli; Edson Borges
Journal:  JBRA Assist Reprod       Date:  2020-01-30

7.  Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study.

Authors:  Gorka Barrenetxea; Juan Antonio García-Velasco; Belén Aragón; Jordi Osset; Max Brosa; Noemí López-Martínez; Buenaventura Coroleu
Journal:  Reprod Biomed Soc Online       Date:  2018-02-21

8.  Intraindividual Embryo Morphokinetics Are Not Affected by a Switch of the Ovarian Stimulation Protocol Between GnRH Agonist vs. Antagonist Regimens in Consecutive Cycles.

Authors:  Jens E Dietrich; Alexander Freis; Franziska Beedgen; Kyra von Horn; Verena Holschbach; Julia Liebscher; Thomas Strowitzki; Ariane Germeyer
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-28       Impact factor: 5.555

9.  Immature oocyte incidence: Contributing factors and effects on mature sibling oocytes in intracytoplasmic sperm injection cycles.

Authors:  Daniela Paes de Almeida Ferreira Braga; Bianca Ferrarini Zanetti; Amanda Souza Setti; Assumpto Iaconelli; Edson Borges
Journal:  JBRA Assist Reprod       Date:  2020-01-30

10.  There is a cycle to cycle variation in ovarian response and pre-hCG serum progesterone level: an analysis of 244 consecutive IVF cycles.

Authors:  Sule Yildiz; Kayhan Yakin; Baris Ata; Ozgur Oktem
Journal:  Sci Rep       Date:  2020-09-25       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.